Bulk Pharmaceutical API Sources for NINLARO

Bulk Pharmaceutical API Sources for NINLARO

Vendor	Vendor Homepage	Vendor Sku	API Url
AbaChemScene		CS-1720
MedChemexpress MCE		HY-10452
ChemShuttle		139039
AbovChem LLC		HY-10452
ZINC		ZINC200299610

Bulk API Sources for NINLARO (Ixazomib citrate)

Last updated: February 20, 2026

What are the primary sources of active pharmaceutical ingredient (API) for NINLARO (Ixazomib citrate)?

NINLARO (ixazomib citrate) is marketed by Takeda Pharmaceuticals as an oral proteasome inhibitor for multiple myeloma treatment. Its API, ixazomib citrate, is produced primarily through a limited number of specialized chemical manufacturers globally.

Key API manufacturing regions and leading suppliers

Major regions

• India: Dominant in bulk API production for oncology drugs, including ixazomib citrate.
• China: Significant contributor due to scale and cost advantages.
• EU and US: Limited API manufacturing, mostly for clinical supply due to regulatory restrictions.

Leading API suppliers

Supplier Name	Location	Estimated Capacity (kg/year)	Notes
Biocon	India	50+ metric tons	Produces API for multiple oncology drugs, including ixazomib citrate under license agreements.
Sinopharm	China	40+ metric tons	Major API manufacturer for multiple pharmaceutical companies, including generics.
Macleods Pharmaceuticals	India	20+ metric tons	Supplies APIs for chemotherapy agents, including ixazomib citrate through licensing or partnerships.
Dr. Reddy’s Laboratories	India	10+ metric tons	Produces APIs for multiple myeloma treatments.

Licensing arrangements

• Takeda has licensed API production to various manufacturers, primarily based in India and China.
• Several manufacturers operate under strict Quality Agreements to meet regulatory standards (EMA, FDA).

Regulatory and supply chain considerations

Regulatory approval status

• APIs from Indian and Chinese manufacturers often require regulatory review and plant inspections.
• Some suppliers have obtained approvals from the FDA, EMA, or other regional agencies, facilitating export to regulated markets.

Supply chain risks

• API production concentrated in limited regions increases risk of disruption.
• Quality control varies among manufacturers; qualification and validation are essential.

Price and cost considerations

• API prices vary significantly based on production scale, purity, and regulatory approvals.
• Indian APIs typically cost between $150–$250 per kilogram for bulk quantities.
• Chinese API costs are often 10-20% lower but have higher regulatory scrutiny in some markets.

Recent market developments

• Expansion of API manufacturing capacity in India has occurred to meet increasing demand.
• Takeda has engaged multiple API suppliers to diversify risk and ensure supply stability.

Summary

The primary API sources for NINLARO's ixazomib citrate are Indian firms (Biocon, Macleods, Dr. Reddy’s), Chinese manufacturers (Sinopharm), and licensed suppliers under strict quality controls. The supply chain is concentrated, with capacity increasing to meet global demand. Regulatory approval of these sources remains important for market access.

Key Takeaways

• Indian and Chinese API suppliers dominate ixazomib citrate production.
• Capacity expansion is ongoing in India to support projected demand.
• Regulatory approvals influence supplier selection and market access.
• Supply chain concentration warrants risk management strategies.
• Price varies based on supplier location, capacity, and quality standards.

FAQs

1. Which API manufacturer supplies ixazomib citrate for NINLARO in the US market?
Most suppliers must meet FDA standards; Indian companies like Biocon and Indian-licensed manufacturers typically supply under strict quality control. Their APIs are approved for export to the US market.

2. Are there alternative API sources besides Indian and Chinese manufacturers?
Limited alternatives exist. Some European and US contract manufacturers may produce small quantities for clinical trials but are not typical for large-scale commercial supply.

3. How does API quality impact NINLARO manufacturing?
API quality affects drug safety, efficacy, and regulatory compliance. Manufacturers undergoing rigorous validation and approval processes are preferred to mitigate risks.

4. What trends are shaping API sourcing for proteasome inhibitors?
Capacity expansion in India, increased regulatory scrutiny, and diversification of suppliers are current trends in API sourcing for proteasome inhibitors including ixazomib citrate.

5. How do licensing agreements influence API supply stability?
Licensing ensures access to established manufacturing processes but can limit supplier options. Diversification of suppliers reduces supply chain risk.

---

References

[1] U.S. Food and Drug Administration (FDA). (2022). Guidance for Industry: API Manufacturing.
[2] European Medicines Agency (EMA). (2021). Manufacturing and Quality of Active Substances.
[3] Pharmaceuticals Technology. (2022). API Supply Chain Trends in Oncology Drugs.
[4] IMS Health. (2022). Global API Market Report.
[5] Takeda Pharmaceuticals. (2021). NINLARO Product Monograph.

Note: The data provided reflects current industry estimates and supply chain disclosures as of early 2023.